Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma
This study has been completed.
Study NCT00352833   Information provided by Fresenius Biotech GmbH

First Received on July 14, 2006.   Last Updated on October 25, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastric Cancer
Gastric Adenocarcinoma
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Stomach Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Stomach Diseases
Interventions listed in this trial
catumaxomab
Additional drug interventions recognized in this trial
Antibodies, Bispecific
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Fresenius Biotech GmbH


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services